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ABSTRACT: The synthonic modeling approach provides a
molecule-centered understanding of the surface properties of
crystals. It has been applied extensively to understand
crystallization processes. This study aimed to investigate the
functional relevance of synthonic modeling to the formulation
of inhalation powders by assessing cohesivity of three active
pharmaceutical ingredients (APIs, ﬂuticasone propionate (FP),
budesonide (Bud), and salbutamol base (SB)) and the
commonly used excipient, α-lactose monohydrate (LMH). It
is found that FP (−11.5 kcal/mol) has a higher cohesive
strength than Bud (−9.9 kcal/mol) or SB (−7.8 kcal/mol). The prediction correlated directly to cohesive strength measurements
using laser diﬀraction, where the airﬂow pressure required for complete dispersion (CPP) was 3.5, 2.0, and 1.0 bar for FP, Bud,
and SB, respectively. The highest cohesive strength was predicted for LMH (−15.9 kcal/mol), which did not correlate with the
CPP value of 2.0 bar (i.e., ranking lower than FP). High FP−LMH adhesive forces (−11.7 kcal/mol) were predicted. However,
aerosolization studies revealed that the FP−LMH blends consisted of agglomerated FP particles with a large median diameter
(∼4−5 μm) that were not disrupted by LMH. Modeling of the crystal and surface chemistry of LMH identiﬁed high electrostatic
and H-bond components of its cohesive energy due to the presence of water and hydroxyl groups in lactose, unlike the APIs. A
direct comparison of the predicted and measured cohesive balance of LMH with APIs will require a more in-depth understanding
of highly hydrogen-bonded systems with respect to the synthonic engineering modeling tool, as well as the inﬂuence of
agglomerate structure on surface−surface contact geometry. Overall, this research has demonstrated the possible application and
relevance of synthonic engineering tools for rapid pre-screening in drug formulation and design.
KEYWORDS: powder dispersion analysis, in silico formulation design, inhalation drug delivery, inter-particle interaction,
molecular and synthonic modeling, salbutamol, ﬂuticasone propionate, budesonide, α-lactose monohydrate, laser diﬀraction,
de-agglomeration
1. INTRODUCTION
The study of interaction forces between particles in
pharmaceutical formulations (e.g., active pharmaceutical
ingredients (APIs) and excipients) has increased in importance
over the past 20 years with the emergence of very sensitive
surface analytical techniques such as atomic force microscopy
(AFM) and inverse gas chromatography (IGC). Physical
interaction between similar particles (e.g., API−API) is
known as cohesive force,1 and the interaction between
heterogeneous particles (e.g., API−excipient) is known as
adhesive force.1 The ability to study adhesive or cohesive
interactions between particles is beneﬁcial in understanding or
even predicting behaviors as diverse as blending operations2
(and the resultant content uniformity) to tablet compaction3,4
or disintegration,5 where surface interactions dictate the
strength of surface contacts. It is not straightforward to detect
these interactions in a formulation by simple experimental
techniques.
The quality-by-design (QbD) approach in pharmaceutical
development is a systematic and holistic approach,6,7 in which
the compatibility test to select the right API(s)−excipient
combination to deliver the critical quality attributes for the drug
product is the foremost step in drug development. There is not
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one single eﬀective method for compatibility testing. For
example, dry powder inhaler formulations depend to some
extent on one or several of the following parameters:
crystallinity, water content, charge, size, shape, ﬂow, and
mechanical properties of the components of the inhaler
formulation.8−10 Therefore, a combination of the many
available techniques (such as AFM, scanning electron
microscopy (SEM), IGC, powder electrostatics, high-perform-
ance liquid chromatography (HPLC), Fourier transform
infrared spectroscopy (FT-IR), and diﬀerential scanning
calorimetry (DSC)) is generally used to test the physical
stability of the formulated drug and/or the chemical
compatibility of API−excipient.11
An understanding of inter-particulate interactions between
the formulated components is of immense importance in the
QbD approach. In inhaled drug delivery the small size required
for particle deposition in the lung (<6 μm),12 inter-particulate
interactions originating from surface forces (van der Waals,
electrostatic, and capillary forces) to dominate over gravita-
tional forces. Micronized drug particles display highly cohesive
behavior and tend to form agglomerates, which must be
eﬀectively dispersed upon inhalation to be suitable for lung
deposition.13 APIs in low-dose inhalation powders are
formulated with coarse “carrier” particles, usually crystalline
lactose monohydrate, which serves primarily as a diluent in the
formulation. However, extensive evidence exists that the use of
carrier particles also serves to improve ﬂow, dose uniformity,
dispersion, and aerosolization of otherwise cohesive particles.14
To gain an understanding of the cohesive and adhesive
interactions between APIs and excipients is therefore an
important pre-formulation requirement in inhaled drug
delivery.
SEM, IGC, AFM, and electrostatics techniques have emerged
as the most popular methods to gain some understanding of
the static and dynamic API−excipient interactions.9,11 Although
suitable for use as complementary techniques to aid in probing
inter-particle interactions, they are not able to directly predict
strength and surface speciﬁcity of API−API and API−excipient
interfacial interactions. The tensile strength and AFM methods
of measuring adhesion force15 are susceptible to inconsistency
due to sample preparation, surface roughness, and surface
chemistry that aﬀect the type and orientation of the functional
groups interacting at the contact points of both surfaces. The
cohesive−adhesive balance (CAB) model based on AFM
measurements2 provides a quantitative method to predict the
strongest inter-particle forces present, i.e., the cohesive force or
the adhesive force in an API−excipient pair. The method allows
predictive ranking of adhesive behavior to understand the
mixing, blending, and aerosolization behavior of inhalation
blends of micronized APIs with lactose.1,16 However, the
technique is not trivial to perform and is still dependent on the
contact area and geometry of the probes and crystal faces under
study, as shown by James and co-authors.17
Surface energy measurements using IGC have been
particularly useful in improving our understanding of the
crystallinity and surface properties of micronized particles.18,19
Particularly, new-generation surface energy analysis (SEA)20,21
is eﬀective at characterizing the surface energy of micronized
particles, including the dispersive and speciﬁc components of
crystal surface free energy. Therefore, IGC is useful for
assessing the interaction forces between particles,22,23 including
cohesive and adhesive interactions of blended particles, and for
predicting dry powder inhaler performance.24 SEA is often used
in combination with other techniques (similarly to CAB
modeling using AFM). Whereas AFM measures adhesive force,
but only for several isolated (and hopefully representative)
particles, IGC/SEA examines more representative surface areas
of bulk powders, but it does not measure actual inter-particulate
contact forces. Both techniques are time-consuming and may
not be cost-eﬀective, especially at the pharmaceutical research
and development stage, where material availability is typically
low.
Laser diﬀraction studies provide a method to measure the
agglomeration state of particles in formulations and have been
used to investigate the aerosolization potential of suspended
APIs25 as well as dry powder inhalation systems. Rapid
screening tests have been proposed to characterize the de-
agglomeration (in terms of the cohesive forces)26,27 of particles
from the critical pressure that is required to disperse particles of
certain size through laser diﬀraction techniques. Although laser
diﬀraction methods require reasonably large amounts of
sample, they do serve to examine materials in a manner that
is representative of in-use powder behavior and may probe
blend structure.28
Thus far, all major methods for studying the forces of
interaction between particles in inhalation powder systems have
disadvantages. In particular, many of the methods must be used
in tandem with each other and are time-consuming or material-
expensive. The in silico model applied in this research adopts a
“synthonic engineering approach” as a pre-screening formula-
tion design tool through the quantitative evaluation of the
interactions between molecular building blocks or functional
groups known as synthons. The balance between the intrinsic
synthons (fully coordinated interactions within the bulk crystal
lattice) and the extrinsic synthons (interactions giving rise to
unsaturation at the interface with the solvent or excipient(s))
provides an understanding of the complex surface properties
and, in general, the likely formulation behavior. In silico
predictive tools have not been widely employed so far beyond
specialist groups, but they oﬀer an attractive alternative in terms
of predicting particle formation3,29 and have found application
in morphological prediction,30 salt/co-crystal former selec-
tion,31 inter-particle interactions,32,33 and nucleation control of
polymorphic forms.34 In the current research, the synthonic
molecular modeling tool using the grid search method is
applied to examine the extrinsic synthons involved in molecule/
surface binding in order to get an understanding of the inter-
particle interactions that underpin the agglomeration and
aerosolization behavior in inhaled formulations. This method
has potential to oﬀer a robust and eﬀective screening approach
or compatibility test to pre-select likely API−excipient
combinations and, through this, to reduce the range of
formulation that must be assessed using conventional
laboratory techniques. The case study systems include an
excipient, α-lactose monohydrate (LMH), and three APIs,
salbutamol (SB), ﬂuticasone propionate (FP), and budesonide
(Bud). The prediction work is validated through independent
experimental de-agglomeration studies using laser diﬀraction
techniques.
2. SYNTHONIC MODELING
Crystallization is the primary method used by the pharmaceut-
ical industry in the isolation and puriﬁcation of APIs from the
upstream synthesis environment. In addition to facilitating the
formation of crystalline particles, the nucleation and growth
stages of the crystallization process can pre-conﬁgure a number
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of the key physicochemical properties that are important in the
utility and performance of drug products downstream (see
Figure 1). In this schematic, nucleation refers to the bulk
nucleation, which is a three-dimensional process having an
eﬀect on the bulk properties, such as size, polymorphism, and
mechanical properties, while the two-dimensional crystal
growth process has an eﬀect on the crystal shape and
agglomeration. Knowledge of the inter-molecular interactions,
in aggregate referred to as synthons, involved in crystal
formation can help us understand, predict, control, and scale-up
crystallization processes. Such details can be derived from the
crystallizing material’s crystallographic structure using molec-
ular modeling techniques.
The synthons mostly consist of isotropic van der Waals and
electrostatic interactions between inter-molecular atom pairs,
together with highly directional H-bonds. The synthonsin
particular, the extrinsic synthonsare important in that they
can potentially have a signiﬁcant impact on the physical and
chemical properties of a crystalline particle, e.g., relative crystal
growth rate, particle shape, reactivity, agglomerability, etc.
Synthonic analysis requires knowledge of the basic chemistry of
the molecules together with details concerning the crystal
lattice and its associated inter-molecular arrangement. Although
such supramolecular science is reasonably well-established, the
manipulation of synthonic interactions in a manner analogous
to that used in chemical (molecular) synthesis has received
little attention in recent years. Synthonic engineering thus
provides the opportunity to exploit synthon directionality and
energetic to understand, design, and potentially control the
physicochemical properties of such molecular assemblies. The
latter is helpful as it enables prediction of product- and quality-
related properties in silico, this reducing, in principle, the need
for lengthy and expensive experimental studies.
2.1. Bulk (Intrinsic) Interactions. Habit comprises a
lattice-energy calculator and energy-based morphology pre-
dictor. Habit analyzes the magnitude of the ratio of the extrinsic
synthons to the intrinsic synthons of the bulk structure.
Comparing the values obtained for diﬀerent crystal faces can,
e.g., be used to predict the external morphology. These
calculations require knowledge of the crystal system, the
chemistry of the molecules, and a suitable inter-atomic
potential. Essentially the approach is to sum the inter-atomic
potential for all the molecules within a given limit of a central
molecule, to produce a molar lattice energy value. Habit has the
following key features:
• Calculate the strength and direction of the inter-
molecular interactions in a crystal structure, providing
also an analysis of the local coordination sphere around a
targeted central molecule.
• Calculate the lattice energy of a fully extended organic
crystal structure and the same for molecular clusters as a
function of their size and shape. Calculations on many
structures may be carried out in batch mode, with the
results written to spread-sheet readable ﬁles.
• Display the lattice energy convergence as a function of
the limiting range of the calculation.
• A choice of potentials (force ﬁelds).
• Calculate the surface attachment energy for any plane
deﬁned by its Miller indices.
• Visualize the morphology and calculate the percentage
surface areas of the simulated morphological forms, the
surface/volume ratio of the particle, and the diameter of
its spherical (volume or surface area) equivalent
diameter.
2.2. Surface (Extrinsic) Interactions. SystSearch is a
simulator which predicts the interaction of the crystal surfaces
with the external environment. SystSearch analyses the extrinsic
synthons and uses a systematic grid-based search to calculate
the possible interaction energies between a probe molecule and
another molecule or with a crystal surface. The probe molecule
can itself be conﬁgured as a surface, thus enabling the
interactions between two surfaces to be probed. This approach
has been used to model the morphology of crystals as a
function of solvent type and/or diﬀerent additive species as well
as to assess the energetics of putative inter-molecular
interactions, such as the molecular pairs associated with salt
and co-crystal former selection as well as inter-particle surface
match associated with solvent-mediated polymorphic trans-
formations and API−excipient interactions. This requires the
same information as Habit plus additional information on the
structure and chemistry of the probe. SystSearch has the
following key features:
• The interaction energy is calculated for the chosen
surface of the crystal structure and the selected probe
molecule by a grid search of possible conﬁgurations of
the molecule relative to the surface. Suitable search
parameters are provided by default.
• There is an option to display the geometrical
conﬁguration information which enables an advanced
user to modify the search parameters.
• The output is displayed as a data window which can be
manipulated to visualize the most stable interaction
energy using a histogram, or the statistics of mean, sum,
or mode of the interaction energy, or energy iso-surfaces
Figure 1. Schematic showing the role played by the functional parameters of crystallization (nucleation and growth) in directing the physical
properties of solid forms that result. Prediction of the outcomes would allow greater control of the ﬁnal product.
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(contour-plot) of the number of binding sites as a
function of their interaction energy.
3. MATERIALS AND METHODS
3.1. Materials. The materials considered for this study are
α-lactose monohydrate and three APIs, salbutamol, ﬂuticasone
propionate, and budesonide. The crystal structures of these
materials (LACTOS11,35 BHHPHE,36 DAXYUX,37 and
SHBUXP1038) are taken from the Cambridge Structural
Database (CSD) for the in silico study.
The suppliers of the above materials for the experimental
work were as follow: budesonide (Bud; LGM Pharma, USA,
batch no. U0015/1V040), ﬂuticasone propionate (FP; LGM
Pharma, USA; FP1, batch no. 458763; FP2, batch no. 5501-B-
11030), Lactohale 300 (mLMH; Frieslands Foods, Domo, The
Netherlands; batch no. 6125224/S), salbutamol base (SB;
Pharm Dev Europe; GWRD, batch no. WC46269), lactose
monohydrate (coarse grade, cLMH; Pﬁzer Ltd., Sandwich, UK;
batch no. 120904-25).
3.2. Computational Method. The molecular and
synthonic modeling approach has two component parts:
prediction of crystal habit based upon the crystallographic
structures, and prediction of the cohesive/adhesive energies.
The molecular modeling approach has two parts: prediction of
crystal habit, followed by in silico prediction of the cohesive/
adhesive energy. The prediction of crystal habit from the crystal
structure is based on an atomistic approach which has been
explained elsewhere.39 The crystal habits for all the materials
are predicted using the attachment energy model. The
attachment energy (Eatt
hkl) is the measure of the energy released
on addition of a growth slice (hkl) to the growing crystal, and is
directly proportional to its relative growth rate (Rhkl) normal to
the surface (hkl). Attachment energies are calculated for all the
materials examined using Habit98,40 and hence the crystal habit
is predicted. Crystal faces with smaller absolute values of
attachment energy are slower growing and have larger relative
surface areas; i.e., they become morphologically dominant
3.2.1. Molecule/Surface Binding. The surface packing
diagrams are generated by the Accelrys software, Materials
Studio version 6.0.41 The intra- and inter-molecular H-bonds
are denoted as blue broken lines in all the ﬁgures. All the
surfaces denoted by white lines are cleaved from the crystal
with one d-spacing deep. The most important surfaces from the
predicted habit were, in turn, selected as the substrate for the
prediction of the adhesive/cohesive interactions of probe
molecules onto the crystal habit surfaces. This was carried out
using the SystSearch which utilizes a grid-based, systematic
search. This systematic search application is an extension to the
approach already applied in a molecular-pair model31 and a
cluster-pair model.33 The current modeling approach generates
an atomistic model of a speciﬁc crystalline surface, with a well-
deﬁned termination which retains complete molecules in the
host surface, and enables a probe molecule to explore the
Figure 2. Schematic representation highlighting the main computational methodology associated with the systematic search. (a) Probe molecule in
the context of the surface and the virtual grids. (b) Cartesian coordinates of the probe molecule with respect to a molecule on the surface with which
it is interacting.
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energy landscape as it interacts with the surface. The probe
molecule can either be an excipient molecule or an API
molecule, and similarly, the surface can either be an excipient
crystal surface or an API crystal surface, thus allowing cohesive
and adhesive interactions to be quantiﬁed. The host crystal
structure is optimized with respect to the Dreiding force ﬁeld,42
but the surface is not relaxed further during the systematic
search by the probe. In all the systematic searches, a slice
thickness of 2 times the inter-planar spacing for the surface
(hkl) is chosen. A three-dimensional virtual grid is generated
adjacent to the crystal-surface model as shown in the schematic
in Figure 2a. A probe molecule, treated as a rigid body, visits
every grid point in turn and is orientated, sequentially, in one of
a speciﬁed number of orientations. The in-plane dimensions of
the search space are periodic (several reticules) but non-
periodic in the direction normal to the crystal surface. Reticular
area is a projection of the unit cell on a surface plane. Reticular
area (Shkl) is calculated from the ratio of the unit cell volume
(Vcell) to the d-spacing (dhkl) as shown in eq 1.
=S V
dhkl hkl
cell
(1)
The search area is further divided into grids deﬁned by the
step size for the translational movement as well as the
orientation of the probe. Generally, the total number of grid
points in the search space is held constant for a set of related
searches. In the in-plane y- and z-directions the step sizes are
expressed in fractional coordinates and relate to the cell axes in-
plane, i.e., the axes which deﬁne the reticule. In the direction
perpendicular to the plane the interval between adjacent grid
points is expressed in units of angstroms. The typical value of
the step size for the parameters that deﬁne the orientation of
the probe molecule is set to 30°. Orientation is deﬁned with
respect to the principal axes of the probe molecule which are
calculated from the Cartesian coordinates of the constituent
atoms without applying mass weighting. A pairwise atom−atom
interaction energy is calculated between the probe molecule, at
the center of a sphere with a cutoﬀ radius of 25 Å, and every
molecule in the surface slab within the sphere. The Cartesian
coordinates of the center of gravity of the probe molecule is
explained in Figure 2b. Interaction energy is calculated for every
grid point location and at that location for all the speciﬁed
orientations of the probe molecule. The program is capable of
listing various statistics such as mean, minimum, total, mode,
distribution, number of favorable sites, etc. from these
calculations.
The most energetically favorable location and orientation of
the isolated probe molecule on the crystal surface were
identiﬁed. Currently the position and orientation of the probe
are not subsequently optimized with respect to the pairwise
interaction energy. The simulations to predict the cohesive
interaction of the three API systems (SP, BUD, SB) are carried
out with one molecule of the API on all the surfaces of its
crystal. In the case of LMH, one molecular pair of lactose and
water is treated as the probe on all the surfaces of the LMH
crystal.
The technique is robust and simple to use; however, it is
important to note that the method is based on some
assumptions, as follows:
• The model calculates and predicts the interaction
between a single molecule and a crystal surface and
does not take cluster−cluster interaction into consid-
eration.
• The crystal lattice is perfect and devoid of any defects.
• Interactions between another molecule and/or other
heterogeneous species are not taken into account.
• The surface can be represented by a termination of the
bulk lattice, and there is no surface reconstruction.
• The probe molecule is treated as a rigid body in the grid
search, and the conformational change due to surface
interactions is not taken into account.
• The growth solvent eﬀects are not explicitly taken into
consideration, i.e., equivalent wetting of the surfaces with
respect to the solid−solid, solid−ﬂuid, and ﬂuid−ﬂuid
inter-molecular interactions for all the crystal faces.
• The model does not take into account the probe
charging eﬀects, i.e., due to speciation.
3.3. Experimental Method. The powder blends were
prepared for experimental assessment of cohesive energy
analysis, dispersive surface energy measurements using IGC,
and aerosolization characterization.
3.3.1. Production of Mixed Powder Blends. Binary ﬁne
particle blends were prepared consisting of FP1 and mLMH
(blend size 1 or 3 g, ratio 1:4, and 1 or 5 g, ratio 1:8 w/w in 15
and 100 mL glass bottles, respectively). Blending was by
geometric mixing, where drug and lactose were added
sequentially in approximately equal volumes to the powder
already contained in the mixing vial. Following each addition,
the blending vessel was placed on a vortex mixer and subjected
to agitation for 60 s, followed by 60 s of stirring with a spatula
to break up any large agglomerates. Up to three ceramic beads
(approximately 10 mm diameter) were added to the vessel for 1
and 3 or 5 g blends, respectively, and the blend was tumbled
using a shaker mixer at 62 rpm for 40 min. As controls, FP1 and
mLMH were subjected to a tumbling process similar to that
used for the mixtures prior to aerosolization assessment.
A similar process was followed for blends of FP2 with coarse-
grade lactose (cLMH, blend size 3 g, 1.4% w/w), with the
exceptions that the blending was performed in 15 mL glass
vials, the blends were not manually triturated with a spatula,
and two 10 mm diameter ceramic beads were employed. Blends
were stored in a desiccator over dry silica before use. Content
uniformity analysis involved assessing drug recovery (n ≥ 6)
using validated HPLC methods. No blend was examined
further unless the coeﬃcient of variance of drug content was
<6%.
3.3.2. Measurement of Powder Cohesion Using Dry
Powder Laser Diﬀraction Analysis. Laser diﬀraction analysis
was performed using a Sympatec HELOS/RODOS instrument
with a rotary feeder dispersion unit (Sympatec GmbH,
Clausthal-Zellerfeld, Germany) using an R3 lens (0.9−175
μm), with a forced stability of 4, according to the analytical
method previously reported.27 By varying the partial pressure
(PP) drop across the dispersion line in the range 0.2−5.0 bar,
the degree of agglomeration (DA) was determined by
normalizing the median particle size measured at each PP (eq
2):
= ×D
D
PP 100
x
m
(2)
where Dm is the particle size at the maximum PP (i.e.,
maximum dispersion force), representing the median particle
diameter at full dispersion, and Dx is the median diameter at
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any other PP. The de-agglomeration curves were analyzed to
calculate the critical primary pressure (CPP) and pressure
required for 50% de-agglomeration (DA50) as reported
previously.27
3.3.3. Surface Energy Determination by Inverse Gas
Chromatography. A 30 cm silanized glass column with an
internal diameter of 3 mm was ﬁlled with 200−300 mg of
sample (FP1, FP2, mLMH, and carrier lactose (cLMH)) and
sealed at each end with silanized glass wool. Samples were
analyzed using an SMS surface energy analyzer (SMS Ltd.,
London, UK). The columns were conditioned under dry
helium for 2 h at 0% relative humidity (RH), using helium as
carrier gas at 303 K. The probe and column temperature were
set at 303 K, and analysis was conducted at 0% RH using a total
ﬂow of 10 sccm (standard cubic centimeters per minute)
during conditioning and analysis cycles. The speciﬁc surface
area of each sample was ﬁrst determined by measuring the
octane adsorption isotherms at 30 °C and 0% RH using the
SEA. The BET speciﬁc surface areas of the samples were
subsequently calculated from the corresponding isotherms,
Figure 3. Molecular packing of α-lactose monohydrate. (a) A pair of lactose and water molecules with their the H-bonding donor and acceptor
atoms. (b) A water molecule is connected to four lactose molecules through inter-molecular H-bonds. Color code: gray, carbon; red, oxygen; white,
hydrogen; broken blue lines, H-bonds; white circle, water molecule. (c−e) Molecular packing diagrams showing the H-bonds formation in pairs of
FP (c), BUD (d), and SB (e) molecules. Color code: gray, carbon; red, oxygen; white, hydrogen; blue, nitrogen; green, ﬂuorine; yellow, sulfur;
broken blue lines, H-bonds.
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within the partial pressure range of 5−35% P/P0. The surface
coverage (n/nm, i.e., ratio of the amount of adsorbed gas to the
BET monolayer adsorbed capacity) at each injection
concentration could then be calculated from the amount
adsorbed (n), obtained from integration of the net retention
volume (VN), versus the equilibrium partial pressure (P/P0) of
each injection (where P and P0 are the equilibrium and
saturated pressure of the adsorbate at the test temperature).
The dead time was calculated using methane, and the surface
coverages employed for surface energy determinations were in
the range 0.005−0.02 n/nm. The non-polar probes employed
were nonane, octane, heptane, and hexane, and dispersive
surface energy was determined using the Shultz method.43 In
addition to the non-polar probes, a range of polar probes were
employed (ethanol, acetone, ethyl acetate, acetonitrile, and
dichloromethane) to determine the speciﬁc (polar acid−base)
surface energy components of these materials. The polar probe
data were added to the Schultz plot, and the vertical distance of
the data points from the alkane line was taken as equal to the
speciﬁc free energy of adsorption (ΔGSP) arising due to polar
interactions with the sample material. The work of cohesion
and adhesion was calculated following the van Oss method after
Traini et al.44
3.3.4. Aerosolization Studies. Aerosolization performance
was assessed for FP−mLMH and FP−cLMH blends according
to pharmacopoeial methods. Size 3 gelatin capsules (Pﬁzer
Global R&D, UK) were ﬁlled with 15 ± 2 or 12.5 ± 0.5 mg of
blend, respectively, and an appropriate number of capsules
actuated in order to achieve suﬃcient drug deposition within
the next-generation impactor (NGI, Copley Scientiﬁc Ltd.,
Nottingham, UK). The impactor plates were coated with a thin
layer of 11% w/v polypropylene glycol dissolved in hexane by
swirling the solution around the plates and leaving them to air-
dry. The NGI was assembled with 15 mL of mobile phase
accurately pipetted into the pre-separator. The airﬂow through
the NGI was set at 60 L/min ± 5% (or 1.4 kPa) across the
monodose inhaler, with a total airﬂow of 4 L drawn through the
inhaler for each capsule actuated.
Figure 4. Predicted morphology and surface chemistry of LMH. (a) Crystal morphology as predicted by Habit. (b) Surface chemistry of LMH at the
(02̅0) surface, which contributes to about 17% of the total crystal surface. (c) Surface chemistry of LMH at the (020) surface, which contributes to
17% of the total crystal surface, showing the molecules forming a zigzag pattern in a direction perpendicular to the surface; the water molecules
shown in yellow circles are very close to the surface.
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The device and capsules were carefully rinsed with
appropriate volumes of washing solvent (range: 20−50 mL)
to collect the drug deposited, ensuring complete dissolution of
recovered drug particles. The NGI induction port and pre-
separator were rinsed with 50 and 100 mL of washing solvent,
respectively. NGI plates 1−5 were washed with 10 mL of
washing solvent, and stages 6−8 were washed with 5 mL of
washing solvent, in both cases by accurate pipet transfer. A
sample of each solution was withdrawn for analysis by HPLC
according to a validated method for FP.45 The washing solvent
was the HPLC mobile phase, a 75:25 (v/v) mixture of
methanol and 0.6% w/v aqueous ammonium acetate. Fine
particle fractions (FPFs) were deﬁned for the mass of deposited
particles with a size less than 5 μm depositing in the NGI, and
the mass median aerodynamic diameter was calculated by
interpolation of the cumulative undersize particle distribution in
accordance with British Pharmacopoeial methods.
4. RESULTS AND DISCUSSION
Results from the in silico studies are given in sections 4.1−4.3,
and the results from the experimental methods are included in
sections 4.4−4.6
4.1. Crystal Chemistry. The molecular chemistry of all the
case study systems is shown in Figure 3. The donor and
acceptor atoms forming the intra- and inter-molecular H-bonds
are shown as broken blue lines. The hydrogen-bonded network
is generated with the Cambridge Crystallographic Database
Software, Mercury.46
The excipient, α-lactose monohydrate (LMH), is a strongly
hydrogen-bonded system, as can be seen in Figure 3a. The pair
of lactose and water molecules together forms 15 inter-
molecular H-bonds with the neighboring lactose and water
molecules and at least one intra-molecular H-bond. Every water
molecule connects four lactose molecules through the H-bonds
Table 1. Percentage Surface Areas of Individual Faceted Faces (Multiplicity Is Not Taken into Consideration) of the Predicted
Morphology of LMH, FP, BUD, and SB (M Refers to the Multiplicity of a Face)
LMH FP BUD SB
face % surface area M face % surface area M face % surface area M face % surface area M
(020) 16.5 1 (200) 15 2 (002) 20.9 2 (200) 20.5 2
(02 ̅0) 17.2 1 (110) 12.2 4 (101) 5.7 4 (002) 4.7 2
(001) 8.6 2 (101) 4.6 4 (011) 7.4 4 (111) 3.4 8
(011) 1.6 2 (011) 0.8 4 (110) 1.4 4 (102) 5.1 4
(100) 5.7 2 (210) 0.6 4
(101 ̅) 2.4 2
(110) 2.4 2
(11 ̅0) 1.1 2
(01 ̅1) 5.3 2
Figure 5. Predicted morphologies of APIs. (a) Fluticasone propionate with (110) facets as the most dominant and (011) as the least dominant
surface. (b) sec-Budesonide with (002) as the dominant faces and (110) as the smallest faces. (c) Salbutamol with the dominant (200) faces and the
smallest (210) faces.
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(Figure 3a). The APIs, FP, Bud, and SB, form two, two, and six
inter-molecular H-bonds, respectively (Figure 3c−e).
4.2. Prediction of Morphology, and Surface Chem-
istry. The predicted morphology of LMH is given in Figure 4.
The percentage of each of the faceted faces over the total
surface area is given in Table 1, and from this table, it is
understood that (02 ̅0) and (020) contribute the most to the
total surface area of the predicted crystal morphology (17%
each) and (11 ̅0), with the least surface area (2%) of the
predicted morphology. The surface chemistry of the dominant
faces is shown in Figure 4b,c. It is seen that both surfaces are
hydrophilic in nature, with the presence of water molecules
(shown in yellow circles) close to the surface. The molecular
packing arrangements are diﬀerent at these two surfaces,
conﬁrming that LMH is a polar crystal; i.e., molecules are
arranged like a net in the plane below the (02 ̅0) surface (Figure
4b), and the molecules form zigzag columns below the (020)
surface (Figure 4c). It should be noted that the predicted
morphology of LMH is from the classical attachment energy
calculations, where the same atomic charges are assigned to the
molecules in the bulk as well as the surfaces. However, for the
prediction of polar morphology (which is not shown here), two
diﬀerent sets of charges need to be assigned, i.e., to the bulk
molecules and to the oncoming molecules forming the surfaces.
The molecular packing diagrams of the other surfaces are
provided in the Supporting Information. The predicted
morphologies of the three APIs are shown in Figure 5a−c,
and the percentage facet areas are listed in Table 1. The (110)
surfaces contribute the most to the total surface area of FP
(∼49%), followed by (200) surfaces (30%) . From the
calculated percentage surface areas of BUD, it is noted that
the (002) surfaces are the dominant surfaces (∼42%), whereas
the (110) surfaces contribute the least (∼6%) to the total
surface area of the crystal morphology. Similarly, from the
surface areas of the individual faces of the predicted
morphology of SB, it is seen that the (200) surfaces contribute
the most (∼41%), followed by the (111) surfaces (∼27%), with
(210) surfaces contributing the least (∼2%) to the total surface
area of the crystal morphology.
4.3. Prediction of the Cohesive and Adhesive
Interaction Using the in Silico Model. The minimum
interaction energy between a probe molecule and a surface is
the strongest interaction or the most stable (preferred)
interaction energy. Table 2 shows the strongest (minimum)
interaction energies of each of the probes on their respective
crystal surfaces. These values are averaged over all the surfaces
of the crystal. The cohesive strength is stronger if the calculated
value is more negative. On this basis, it can be seen that among
the APIs, FP is the most cohesive, followed by Bud and SB.
However, LMH or lactose molecule on its own as the probe
results in higher cohesive strengths than any API particle
(Table 2). The reason for this probably reﬂects the fact that the
solid-state chemistry of LMH is dominated by an extensive
network of strong and highly directed inter-molecular H-bonds,
and the contribution from these to the inter-particulate forces
was computed to be a signiﬁcant component of the cohesive
interactions (see Figure 6) These show the absolute values of
interaction energies in this cohesive interaction, whereas in the
APIs the contribution of the isotropic van der Waals
interactions are much higher than the electrostatic or the
hydrogen-bonded contributions. The important contribution of
polar interactions in deﬁning cohesion of LMH has been
reported previously using IGC,47 which revealed that the polar
surface energy was almost 3 times higher than the dispersive
surface energy. Thus, the order of cohesive strength is (more
negative to less negative) FP > Bud > SB. The adhesive
strengths of FP on eight LMH surfaces were predicted in the
same way as the cohesive strengths. The average adhesive
energy of FP with LMH is very similar to the FP/FP cohesive
energy (Table 3).
Table 2. Cohesive Energy Prediction from Synthonic Modeling Using the Minimum Interaction Energy
FP Bud SB LMH
form
strongest (minimum)
interaction energy
(kcal/mol) form
strongest (minimum)
interaction energy
(kcal/mol) form
strongest (minimum)
interaction energy
(kcal/mol) form
strongest (minimum)
interaction energy
(kcal/mol)
{200} −12.96 {002} −8.69 {200} −7.75 {020} −17.32
{110} −9.26 {101} −10.75 {002} −7.62 {001} −15.64
{101} −13.22 {011} −9.27 {111} −7.73 {011} −14.24
{011} −10.61 {110} −11.11 {102} −8.34 {100} −16.81
{210} −7.44 {101 ̅} −14.51
{110} −16.23
{02 ̅0} −14.66
{01 ̅1} −14.66
average −11.51 −9.96 −7.77 −15.85
Figure 6. Breakdown of cohesive energy showing that, in LMH and
anhydrous lactose, a high percentage of cohesive interaction comes
from the inter- and intra-molecular H-bonds and the electrostatic
contribution when compared to the APIs.
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4.4. Measurement of Powder Cohesion Using Dry
Powder Laser Diﬀraction Analysis. Powder dispersibility
and de-agglomeration eﬃciency were assessed for the
micronized pure materials (Figure 7) and blends of mLMH−
FP1 using laser diﬀraction analysis. Figure 7 presents the de-
agglomeration curves for SB, mLMH, FP, and Bud, which
demonstrated a range of powder de-agglomeration and
dispersion behaviors. Due to the large carrier size of the FP−
CL blends, it was inappropriate to apply the de-agglomeration
analysis27 to these blends. Instead, the eﬃciency of dispersal
and de-agglomeration was assessed by impaction analysis. Laser
diﬀraction analysis has been demonstrated to be a useful
technique for characterizing the aerosolization behavior of a
number of particles for inhalation.22 The technique has several
limitations, as previously reported, including the possible
fragmentation of particles under the dispersion pressure, high
limits of detection for the presence of particles in the laser
beam, the sensitivity of the instrument to vibration, and,
because it is a volumetric technique, the potential for a small
number of large agglomerates to skew the estimation of de-
agglomeration. Nevertheless, laser diﬀraction oﬀers beneﬁts in
estimating inter-particulate cohesion. The method does not
require powder pre-conditioning (unlike powder rheometry
and shear cells); it is an ensemble powder technique capable of
studying large numbers of particles in a powder bed (unlike
AFM). Finally, the forces required both for de-agglomeration of
the powder bed and to overcome individual particle−particle
adhesion (i.e., the critical pressure parameter) are investigated
using conditions consistent with powder breakup during
inhalation, namely under airﬂow.
The de-agglomeration analysis demonstrated the relative ease
of de-agglomeration of SB and mLMH. More energy input was
required to de-agglomerate Bud, and FP demonstrated very
poor and heterogeneous de-agglomeration, indicating the
presence of particles with high heterogeneity of agglomerate
cohesion force. Following data normalization and lineariza-
tion,27 the linearity was found to be good for all powders (range
for R2 = 0.905−0.999). In accordance with previous analysis,
the CPP, i.e., the pressure required to achieve 50% de-
agglomeration (DA50), was determined from the linear ﬁt
(Table 4).
The results presented in Table 4 indicate a range of powder
de-agglomeration behaviors. The CPP expresses the airﬂow
pressure required to fully disperse the most cohesive
agglomerates in the powder. It can be seen that SB represented
the least cohesive powder and FP had the most cohesive
agglomerates. The values of the DA50 suggest that SB, Bud, and
mLMH all achieved eﬀective dispersal at low airﬂow pressures
Table 3. Adhesive Energy Prediction from Synthonic
Modeling Using the Minimum Interaction Energy for FP on
α-Lactose Monohydrate
face strongest energy (kcal/mol)
(110) −12.47
(100) −13.13
(11 ̅0) −13.33
(020) −11.27
(011) −11.19
(101 ̅) −9.53
(001) −12.00
(01 ̅ ) −10.63
average −11.69
Figure 7. De-agglomeration proﬁles derived from particle size data
generated by Sympatec HELOS/RODOS laser diﬀraction (using the
rotary feeder) at primary pressures in the range 0.2−5.0 bar (inset is a
magniﬁcation of the 0−1.0 bar region). Particle size data (i.e., DA50
values) were normalized using the Dm/Dx approach for the powders
budesonide (Bud, red line), ﬂuticasone propionate (FP1, blue line),
lactohale 300 (mLac, green line), and salbutamol base (SB, purple
line) (mean ± SD, n = 3). The data show the relative ease with which
SB reaches full dispersion at a low airﬂow pressure drop. Bud and
mLac undergo dispersion at low pressure drop values but require a
higher pressure for full dispersion to be achieved. FP fails to disperse
fully until high dispersion airﬂow is applied and exhibits heterogeneity
in dispersibility.
Table 4. De-agglomeration Analysis of Pharmaceutical
Powders Including Micronized and Coarse Active
Pharmaceutical Ingredients and Excipientsa
sampleb R2
CPP
(bar)
DA50
(bar) FPF (%RD)
MMAD
(μm)
SB 0.9979 1.0 0.25
mLMH 0.9997 2.0 0.23
Bud 0.9995 2.0 0.32
FP1 0.9049 3.5 1.15
mLMH
(processed)
0.9897 1.2 0.07
FP1
(processed)
0.9832 4.0 0.48 27.98 ± 2.95 4.40 ± 0.27
FP1−mLMH
1:5
0.9849 3.5 0.61 19.36 ± 2.38 4.76 ± 0.17
FP1−mLMH
1:6
0.9773 3.5 0.57 22.43 ± 4.18 4.73 ± 0.39
FP2−cLMH 7.95 ± 0.65 4.22 ± 0.07
aDe-agglomeration analysis was performed by laser diﬀraction for
micronized substances (derived parameters: critical primary pressure
(CPP) and ease of de-agglomeration (DA50); R
2 indicates linearity.
Formulated blends (mean ± SD, n ≥ 3) were assessed for de-
agglomeration by inertial impaction (determined parameters: ﬁne
particle fraction (FPF < 5 μm) expressed as a percentage of the total
recovered dose (RD) and mass median aerodynamic diameter
(MMAD)) of micronized substances co-formulated in ﬁne particle
blends. bSB, micronized salbutamol base; mLMH, micronized lactose;
Bud, micronized budesonide; FP, micronized ﬂuticasone propionate;
FP−mLMH, FP mixed with micronized lactose; FP2−cLMH, 1.8% FP
with coarse lactose.
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(0.23−0.32 bar); however, both mLMH and Bud contained a
population of agglomerates which required higher dispersion
forces to achieve full de-agglomeration. FP represents a very
cohesive powder which is dispersed into large agglomerates at
low pressures (DA50 = 1.15 bar), and these agglomerates have
high cohesive forces, requiring 3.0 bar airﬂow pressure for full
de-agglomeration.
The rapid decrease in the aerosol median diameter for SB
upon application of dispersing pressures and attainment of full
de-agglomeration at low forces indicates low and homogeneous
forces of SB−SB cohesion. Such observations are consistent
with ﬂuidization via an erosion mechanism, where a stream of
de-agglomerated particles is continually entrained into the
airﬂow, even at low ﬂow rates.48,49 A similar behavior was seen
for Bud and mLMH, albeit with a greater heterogeneity in the
Bud−Bud and mLMH−mLMH cohesive force distribution, as
shown by the greater diﬀerence between DA50 and CPP values.
The heterogeneity in the forces of inter-particulate interaction
is clearly observable in the FP dispersion curves, with high
standard deviations in the measured agglomerate sizes across
the dispersing pressures for FP. This highlighted agglomerate
size heterogeneity during dispersion indicates that, under a
given level of shear, there will be mixed populations of large-to-
medium-sized, highly cohesive agglomerates and de-agglom-
erated particles aerosolized from the powder bed.
The eﬀect of a typical powder processing operation
(tumbling/blending) was also assessed using powder de-
agglomeration analysis. It can be seen that the tumbling of
FP worsened the heterogeneity of cohesive interactions in the
powder blend, which may be related to powder micro-
structure.26 The lowering of the DA50 for FP indicated an
improved aerosolization of an easily dispersed population of
particles from the powder bed (i.e., more particles dispersed
into individual particles and smaller agglomerates at lower
airﬂow rates). However, the CPP remained high (4.0 bar),
indicating the diﬃculty in dispersing the cohesive agglomerates
into an aerosol of fully dispersed (individual) particles. For
mLMH, the powder dispersed more readily, and the tumbling
also served to disrupt the cohesive forces of the powder, leading
to lower airﬂow forces required to disrupt even the most
cohesive mLMH agglomerates.
4.5. Pre-screening Formulation Interactions through
Adhesive Force Determination. In inhaled formulations, the
balance of the cohesive to adhesive forces is crucial to the
formulation performance in carrier-based blends. Frequently,
mLMH is added to blends to alter the CAB. Therefore, it was
of interest to examine the rapid screening ability of synthonic
engineering and the powder dispersal approach to CABs. To
use the synthonic approach to determine the adhesive strengths
of FP with LMH, the APIs were treated as probe systems, and
their interactions on eight surfaces of LMH are tabulated in
Table 3. The strongest energy on each of these surfaces was
recorded from the simulation. It is revealed in this table that the
adhesive strengths of the APIs on all the LMH surfaces were
very similar, and although FP−LMH adhesive strength was
similar to the FP−FP cohesive strength, it was lower than the
LMH−LMH cohesive strength.
Mixing FP with mLMH in two diﬀerent proportions revealed
an interesting behavior. The materials were blended with the
intention to produce FP-rich and mLMH-rich blends; however,
the actual FP:mLMH ratios determined during content
uniformity testing were 1:5 and 1:6, indicating that mLMH-
rich blends resulted. Upon analysis, a low DA50 was observed
(indicating ready dispersal of the powder into an aerosol
cloud), but a high CPP value was maintained, characteristic of
FP on its own. This suggests that the addition of mLMH to FP
was unable to disrupt the cohesive interactions of the FP
agglomerates; rather, it only altered the bulk powder cohesion.
Therefore, the aerosol that is formed is hypothesized to consist
of agglomerates of FP which still require high airﬂow forces to
de-agglomerate.
The latter ﬁndings are supported by the study of surface
cohesion of FP by SEA. All samples of micronized material
displayed heterogeneous surface energy distributions, and the
dispersive component contributed to the major part of the total
surface energy (data not presented). For means of comparison
with the computational predictions, the surface energy values
corresponding to a surface coverage of 0.01 n/nm are presented
(Table 5) in order to probe the highest energy surface sites on
the drug and excipient materials. The surface energy of mFP1
and mLMH both demonstrated predominantly dispersive
components. The work of adhesion between the two materials
was determined to be was ∼113.7 mJ/m2 for mLMH−FP
interactions. The ﬁndings suggest that the interaction energy
between mLMH and FP would be insuﬃcient to break-up the
strongest mLMH cohesive interactions, and hence segregation
into FP-rich and mLMH-rich blend regions was predicted. The
surface of cLMH was more polar than that of mLMH and
exhibited a work of cohesion of ∼155 mJ/m2 for cLMH. The
work of adhesion of FP2−cLMH was ∼123 mJ/m2, indicating
that, similar to blending with mLMH, FP particles are unlikely
to form adhesive interactions with cLMH. The latter ﬁndings
were in broad agreement with the aerosolization measurements
of de-agglomeration (where addition of LMH to FP failed to
break-up agglomerates during aerosolization, Table 4) and with
the computational predictions (section 4.3). Although it is
accepted that the probing of only the most energetic surface
sites through the SEA is a reductionist approach, the concept is
compatible with the “active site” hypothesis50 of dry powder
inhalation blend formation.
4.6. Aerosolization Analysis. A typical particle deposition
proﬁle for an FP blend following aerosolization at 60 L/min (or
1.4 kPa) into the next-generation impactor is shown in Figure 8
for the FP2−cLMH blend. The aerosolization performance for
both the cLMH and mLMH blends presented in Table 4
indicates the lack of improvement in ﬁne particle dispersion
following blending of FP with lactose monohydrate. The ﬁne
Table 5. Dispersive Surface Energy, Speciﬁc Surface Energy,
and Work of Cohesion or Adhesion for Inhalation Particles
samplea
dispersive surface
energy (mJ/m2)
speciﬁc surface
energy (mJ/m2)
work of cohesion/
adhesion (mJ/m2)
FP1 47.9 6.3 108.6
mLMH 52.5 6.9 119.0
FP1−
mLMH
113.7
FP2 42.8 5.8 97.2
cLMH 65.3 12.3 155.3
FP2−
cLMH
123.2
aFP1, micronized ﬂuticasone propionate (batch no. 458763, LGM
Pharma); FP2, micronized ﬂuticasone propionate (batch no. 5501-B-
11030, LGM Pharma); mLMH, micronized lactose monohydrate
(Lactohale LH300); cLMH, coarse-grade lactose monohydrate (batch
no. 120904-25, Pﬁzer Global Research & Development).
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particle fraction (FPF < 5 μm) for FP alone was low (∼26%),
and the dispersed particles possessed a large mass median
aerodynamic diameter (∼4.50 μm), with no statistically
signiﬁcant improvement in the dispersion upon blending with
mLMH (p > 0.05, ANOVA and posthoc Tukey’s test). Upon
blending with coarse lactose, the FPF was considerably lower (p
< 0.05) compared to that of FP alone; however, once more
there was no signiﬁcant decrease in the aerodynamic diameter.
The deposition proﬁle for FP2−cLMH blends (representative
of a DPI product) showed a pronounced pre-separator
deposition fraction as well as a high MMAD value. This
suggests the aerosolization of large agglomerates of the drug
and/or the poor removal of surface-adhered FP particles. A
scanning electron micrograph of the FP2−cLMH blend before
aerosolization (Figure 9) supports that argument, with large
agglomerates as well as some individual identiﬁable particles
stuck to the surface of the carrier particle. In order to achieve a
high FPF, both agglomerates and individual drug particles
would need to be removed from the carrier surface by
aerodynamic shear forces and impaction within the device.
However, poor de-agglomeration owing to the high cohesive
force distribution for the FP−FP interactions would lead to
ineﬃcient de-agglomeration and persistence of the high
MMAD, even following blending with the carrier.
5. APPLICABILITY AND LIMITATIONS OF THE RAPID
PREDICTION FORMULATION ENGINEERING
APPROACHES
The use of an atom−atom systematic search computational
approach has proved powerful for the in silico prediction of
cohesive forces of pharmaceutical powders. A rank-order
correlation was achieved with experimental determination of
de-agglomeration under airﬂow dispersion in the case of
micronized particles of APIs, where surface energies were found
to be dominated by non-polar van der Waals dispersion forces.
The computational modeling of LMH surface energy predicted
a substantially higher cohesive force than any of the APIs,
which was not in keeping with the powder dispersal analysis for
mLMH. Furthermore, although the modeling approach
predicted FP to have an adhesively balanced interaction with
LMH, the prediction was not veriﬁed by experimental
observations using powder dispersal (Table 4) or SEA
characterization for mLMH. Reports have suggested that FP
has adhesive interactions with LMH in dry powder
formulations.51 However, researchers from the same group
have also shown, when performing functional performance
Figure 8. Deposition proﬁle of ﬂuticasone propionate in the next-
generation impactor following aerosolization. S1−S8 indicate the stage
number and respective aerodynamic cutoﬀ diameter of the stage (in
μm at 60 L/min). Data represent mean ± SD, n = 3. The formulation
exhibits poor dispersion of FP into respirable particles (fraction
depositing on stages 2−8). Instead, large drug aggregates and drug
which remains adhered to the carrier lactose particles predominate
(i.e., high pre-separator deposition).
Figure 9. Scanning electron microscopy images of a 1.38% w/w dry powder blend of ﬂuticasone propionate with coarse lactose monohydrate (left),
micronized lactose (LH300), and micronized ﬂuticasone propionate (FP). FP agglomerates and individual FP particles are visible on the surface of
the coarse carrier lactose.
Molecular Pharmaceutics Article
dx.doi.org/10.1021/mp500335w | Mol. Pharmaceutics 2015, 12, 18−3329
testing, that the cohesive agglomeration of FP within a
formulation depends critically on the processing history of
the micronized powder.10 In our experimental analysis with
FP2 and cLMH, SEA incorporating polar probes indicated that
an adhesive FP−cLMH interaction would be suﬃcient to
disrupt cohesive FP−FP interactions but not cLMH−cLMH
interactions. It is therefore appropriate to consider several
points:
• the behavior of powders compared to individual
particles;
• the limitations of the surface energy by experimental
determination in the current report; and
• the assumptions of the synthonic engineering approach.
When formulating powders suitable for inhalation, the high
speciﬁc surface area of the micrometer-sized particles results in
particles cohering together (e.g., Figure 9). Cohesion may be
aided by surface activation of the powders due to milling.18,52
Therefore, the principal interest during formulation is in
disrupting the cohesive agglomerates to ensure (a) aerosoliza-
tion or (b) interactive mixing with formulation components.
With respect to aerosolization, excellent agreement was
observed between the dispersal analysis of principally non-
polar compounds and the synthonic modeling predictions.
However, assessment of the polar LMH was found to correlate
poorly to the functional measurements, and indeed LMH was
predicted to be the most cohesive of materials studied. It
should be borne in mind that the powders consist of collections
of agglomerates which interact with inter-agglomerate adhesion
forces, as well as inter-particulate interactions within the
agglomerates.23 Therefore, although the synthonic modeling
approach applied in this study assumes unhindered surface
contact between the probe molecule and a crystal surface, this
situation is unlikely to exist in the more representative case of a
practical powder system, where the exact topochemical
alignment between API and the mLMH excipient, despite its
higher interaction energy, might be less favored statistically
when considered in competition with the more stochastic
isotropic dispersive interactions. In addition, the intra-
agglomerate and inter-agglomerate porosity (sensitive to
particle density, shape, charge, and size distribution, including
the presence of “ﬁne lactose” which reduced carrier−carrier
cohesive forces) will also play a role in the cohesion process
through its dictation of the extent of cohering contact points
and permeability to the dispersing airﬂow,48 respectively.
Therefore, although the cohesion of LMH is predicted to be
highest, this would require the highest energy sites to be closely
aligned with each other either within the particles or the
agglomerate. Mindful of the anomaly with respect to the polar
mLMH, an alternative approach would be to use the more
computational demanding surface−surface systematic ap-
proach,32,33 through which the energy landscape between two
surfaces can be probed and the assumption inherent in the
molecule−surface modeling removed. If the above supposition
were to be true, then a much sharper interaction minimum
would be expected in the case of mLMH when compared to the
APIs. Further work is planned to test this supposition.
SEA of LMH and FP correlated well to the predictions in
terms of ranking of cohesive and adhesive forces, with cLMH
found to have the highest cohesive interaction of all materials
tested when polar probes were included. However, the polar
contribution of LMH is profoundly aﬀected by the presence of
surface moisture,47 which the IGC data could not take into
account since it was performed at 0% RH. It was appropriate
for the purposes of the current study to consider surface energy
distributions at 0% RH for eﬀective comparison with the
synthonic modeling approaches. The presence of water vapor
can contribute to the magnitude of cohesive (and adhesive)
interactions under in-use conditions of many lactose-based
formulations.53 All aerosolization studies were performed with
RH < 50%, at which the adsorption of water vapor to FP
surfaces is low54 and unexpected to alter cohesion forces.
Furthermore, although mLMH is susceptible to surface
adsorption and condensation of water vapor, previous studies
have shown no impact of RH < 65% on blends of FP with
cLMH.55 In developing the rapid prediction tools further, it will
be important to perform SEA at a range of RH levels as well as
to incorporate surface capillary moisture interactions in
synthonic modeling. It is also important to consider that
powders for inhalation demonstrate heterogeneity of surface
energy distributions. By probing only the highest surface energy
sites using low surface coverage methods,56 an unrealistic
indication of the forces of interaction will be determined. For
example, the highest energy FP surface sites may well be able to
adhere to the lowest energy cLMH sites, but they would be
unlikely to disrupt the most cohesive of cLMH interactions.
Thus, it can be seen in Figure 9 that FP particles have indeed
adhered as individual particles to several sites on the lactose
carrier particle. Because the blending process employed was a
low-shear process, it is unlikely that cohesive agglomerates of
FP2 starting material would have been disrupted to enable the
FP−cLMH adhesion to occur. Assuming similar energy
distributions for mLMH and cLMH (i.e., including polar
surface energy), it is unlikely that low shear tumbling would be
suﬃcient to disrupt mLMH−mLMH (or cLMH−cLMH) and
FP−FP interactions to facilitate the FP−LMH interactions that
were predicted to be favorable from the synthonic modeling
calculations. The latter discussion is supported by impaction
analysis, where the lack of a change in MMAD when FP was
blended with an excess of mLMH or cLMH demonstrated the
existence of cohesive FP agglomerates in the blends.
6. CONCLUSIONS
The ability of the synthonic modeling approach to provide a
molecular-level understanding of the surface properties of
inhalation powders was demonstrated by assessing the
cohesivity of three active pharmaceutical ingredients (API,
ﬂuticasone propionate (FP), budesonide (Bud), and salbutamol
base (SB)) and the commonly used excipient, α-lactose
monohydrate (LMH). The predictions showed that FP
(−11.5 kcal/mol) has the highest cohesive strength when
compared to Bud (−9.9 kcal/mol) or SB (−7.8 kcal/mol), and
this prediction of cohesive strength ranking validates well the
cohesive strength measurements using laser diﬀraction from the
airﬂow pressure required for complete dispersion (CPP), which
were 3.5, 2.0, and 1.0 bar for FP, Bud, and SB, respectively. The
highest cohesive strength, as predicted for LMH (−15.9 kcal/
mol), did not correlate with the experimental CPP value of 2.0
bar (i.e., ranking lower than FP), and this can be attributed
mainly to the presence of water and hydroxyl groups in lactose,
which lead to very high electrostatic and H-bond components
of the cohesive energy, unlike in the APIs. A direct comparison
of the predicted and measured cohesive balance of LMH with
APIs will require a more in-depth understanding of highly
hydrogen-bonded systems using the synthonic engineering
modeling tools, In addition the application of a more
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computationally intense surface−surface systematic approach
will be required.
Despite the limiting assumptions of the synthonic modeling
approach, it has proved a powerful characterization tool for
predicting inter-particulate interactions in the practical powder
systems important in drug product formulation. The correlation
of the predicted cohesive rank order with the functional
dispersal assessment for the non-polar APIs was promising. In
addition, in a carrier-based lactose blend, similar predictions of
adhesive potential for FP−cLMH were made using the
synthonic modeling calculations and inﬁnite dilution IGC
incorporating polar and non-polar probe gases. It has not
escaped our attention that synthonic modeling could have
utility in drug product formulation design; in particular, they
could be used to guide excipient choice and processing
conditions (e.g., high versus low shear blending) and to predict
consistency of performance in the development of high-quality
and low-variability drug products using a quality-by-design
approach.
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